BOC-CCK-4, CCK(B) receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze

Neuropeptides

Volumn 33, Issue 1, 1999, Pages 63-69

  Koks S ^a   Soosaar, A ^a   Voikar V ^a   Bourin, M ^b   Vasar, E ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DEVAZEPIDE; MORPHINE; MU OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALOXONE; TETRAGASTRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; EXPLORATORY BEHAVIOR; LOCOMOTION; MAZE TEST; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANIMALIA;

EID: 0033082791     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1054/npep.1999.0015     Document Type: Article

References (25)

1. Motta V, Brandao ML. Aversive and anti-aversive effects of morphine in the dorsal periaquaductal gray of rats submitted to the elevated plus-maze test. Pharmacol Biochem Behav 1993; 44: 119-125.
2. Privette TH, Terrian DM. Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacol 1995; 118: 444-450.
3. Stengaard-Pedersen K, Larsson LI. Localization and opiate receptor binding of enkephalin, CCK, and ACTH/β-endorphin in the rat central nervous system. Peptides (suppl) 1981; 2: 3-19.
4. Skinner K, Busbaum AI, Fields HL. Cholecystokinin and enkephalin in brain stem pain modulating circuits. NeuroReport 1997; 8: 2995-2998.
5. Gall C, Lauterborn J, Burks D, Seroogy K. Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res 1987; 403: 403-408.
6. 5-enkephalin-, and dynorphin A (1-8)-like material in the spinal cord and dorsal root ganglia of adult rats. Effects of dorsal rhizotomy and neonatal capsaicin. J Neurochem 1990; 55: 1122-1130.
7. Moran TH, Robinson PH, Goldrich MS, McHugh PR. Two brain cholecystokinin receptors: Implications for behavioural actions. Brain Res 1986; 362: 175-179.
8. Wank SA. Cholecystokinin receptors. Am J Physiol 1995; 269: G628-646.
9. B receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacol 1995; 120: 400-408.
10. B antagonist PD-134,308 facilitates rewading effects of endogenous enkephalins but does not induce place preference in rats. Psychopharmacol 1996; 123: 119-126.
11. B receptor antagonist. Psychopharmacol 1997; 131: 79-85.
12. Valverde O, Maldonado R, Fournie-Zaluski MC, Roques BP. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 1994; 270: 77-88.
13. Valverde O, Roques BP. Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats. Neurosci Lett 1998; 244: 37-40.
14. Shlik J, Vasar E, Bradwejn J. Cholecystokinin and Psychiatric Disorders. Role in Aetiology and Potential of Receptor Antagonists in Therapy. CNS Drugs 1997; 8: 134-152.
15. Kõks S, Soosaar A, Võkar V et al. Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokin agonists in elevated plus-maze. Neuropeptides, 1998; 32: 235-240.
16. Handley SL, Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear' - Motivated behaviour. Naunyn-Schmiedeberg's Arch Pharmacol 1984; 327: 1-5.
17. Pellow S, Chopin P, File SE, Briley M. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety ib the rat. J Neurosci Meth 1985; 14: 149-167.
18. Allikmets L, Vasar E. Sensitization of male rats to aggressive behaviour. Zh. Vyssh. Nerv. Deiat. 1982; 32: 130-135.
19. Lang A, Harro J, Soosaar A et al. Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. Naunyn-Schmiedeberg's Arch Pharmacol 1995; 351: 363-370.
20. Vasar E, Kõks S, Volke V, Võikar V. Cholecystokinin in animal models of anxiety. Biol Psychiatry 1997; 42, 1S: 196-197.
21. B receptors mediate the regulation of exploratory behaviour in the rat. Eur J Pharmacol 1991; 193: 379-381.
22. Benoliel JJ, Becker C, Mauborgue A, Bourgoin S, Hamon M, Cesselin F. Interactions between central opioidergic and cholecystokininergic systems in rats: Possible significance for the development of opioid tolerance. Bull Acad Natl Med 1998; 182: 311-324.
23. Wiertelak EP, Maier SF, Watkins LR. Cholecystokinin antianalgesia: Safety cues abolish morphine analgesia. Science 1992; 256: 830-833.
24. Lavinge GJ, Millington WR, Mueller GP. The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment. Neuropeptides 1992; 21: 119-129.
25. Benedetti F, Amanzio M, CAsadio C, Oliaro A, Maggi G. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 1997; 71: 135-140.